Citations

Clear

1446 citation(s) found for "Howard, F".

Bone marrow involvement by ATTR amyloid is common in cardiac amyloidosis patients and may signal advanced-stage disease
Dasari, Surendra , Chiu, April , Theis, Jason D. , Vrana, Julie A. , Kurtin, Paul J. , Dao, Linda N. , Howard, Matthew T., Grogan, Martha , Rech, Karen L. , McPhail, Ellen Darcy , Dispenzieri, Angela

Mayo Clinic

American Journal of Clinical Pathology | October 31, 2021 | Volume: 156 | Issue: Supplement_1 | Pages: S94-S94

10.1093/ajcp/aqab191.200 Get It

Abstract Introduction/Objective Amyloidosis encompasses a heterogeneous group of disorders characterized by abnormal deposition of misfolded proteins leading to progressive organ failure. Accurate amyloid typing is essential for proper patient management, as treatment regimens vary dramatically across different types. Bone marrow (BM) biopsy, in conjunction with fat pad aspiration/biopsy, is often the first step in patients with suspected amyloidosis. Although BM involvement by AL amyloid has been previously characterized, little is known about the incidence, morphology and clinical phenotype of non-AL amyloid in BM. Methods/Case Report We retrospectively identified 1469 BM biopsies by querying our reference laboratory database of 19,298 specimens from myriad anatomic sites typed by mass spectrometry-based proteomics (LC-MS/MS). These were reviewed for frequency of amyloid types (N=1469), distribution of amyloid deposits (N=139), and clinical phenotypes (N=345), with particular emphases on cardiac involvement. Results (if a Case Study enter NA) We identified the following amyloid types: AL (N=1172; 79.8%), ATTR (transthyretin) (N=240; 16.3%), AH (immunoglobulin heavy chain) (N=38; 2.6%), AA (serum amyloid A) (N=17; 1.2%), and Aβ2M (β2-microglobulin) (N=2; 0.1%). ATTR deposits showed striking predilection for periosteal soft tissue and/or periosteal vessels, and rarely involved BM stroma and/or interstitial vessels, while AL variably involved these compartments. AA primarily involved interstitial vessels. Both AL and ATTR cases commonly had a monoclonal gammopathy (AL: 92.9%; ATTR: 62.5%) with concomitant cardiac amyloidosis (AL: 91.6%; ATTR: 100%). Compared to AL, ATTR patients had higher stage cardiac amyloidosis and lower overall survival. Conclusion ATTR is common in BM, constituting16.3% of cases in our cohort. Rarer amyloid types, such as AA, AH and AB2M can also occur in BM. ATTR was frequently identified in patients with concomitant monoclonal gammopathy, in whom AL may have been suspected. Although ATTR deposits have distinctive morphologic distribution, primarily involving periosteal soft tissue and/or periosteal vessels and rarely involving BM stroma and/or interstitial vessels, there is considerable morphologic overlap with AL. Therefore, it is imperative to type BM amyloidosis, preferably by LC-MS/MS, to ensure proper patient management. Furthermore, BM involvement by ATTR may be a marker for advanced stage of disease.
Biological Variability of Small Dense LDL, HDL3, and Triglyceride-Rich Lipoprotein Cholesterol
Fatica, Erica M. , Jenkins, Sarah Howard, Scott, Renee, Block, Darci R , Meeusen, Jeffrey W. , Baumann, N, Saenger, Amy K., Donato, Leslie J.

Mayo Clinic

American Journal of Clinical Pathology | October 31, 2021 | Volume: 156 | Issue: Supplement_1 | Pages: S4-S4

10.1093/ajcp/aqab189.006 Get It

Abstract The guideline-recommended lipid panel for cardiovascular disease (CVD) risk assessment measures total cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, and calculated low-density lipoprotein (LDL) cholesterol. Measured cholesterol in subfractions of HDL and LDL purportedly improve CVD risk prediction. Homogenous enzymatic methods are now available for measurement of the cholesterol within small dense LDL (sLDL), small dense HDL (HDL3), and triglyceride-rich lipoproteins (TRL). For meaningful interpretation of these measurements, an understanding of the potential sources and extent of result variability is needed. The smallest difference between serial measurements within a patient that likely reflects a change in clinical status is called the reference change value (RCV). Biological variability and reference change values (RCV) are well-characterized for basic lipids but there is limited information for sLDL, HDL3 or TRL. The objective of this study was to determine intra- and inter-individual variability for sLDL, HDL3, and TRL in a healthy reference population. Serum samples were collected from 24 healthy subjects (n=14 female/10 male) daily for three days (non-fasting), daily for five days (fasting), weekly for four weeks (fasting), and monthly for 7 months (fasting). sLDL, HDL3, and TRL cholesterol were measured in duplicate by enzymatic colorimetric assays (Denka, Japan) on a Roche Cobas c501. Each source of variability (between subject, within subject, and analytical) was calculated using random-effects regression models to estimate each variance component including the overall variation, standard deviation (SD), coefficient of variation (CV), and proportion of total variance (between-subject, within-subject, and analytical). Using these analytical and biological variances, the reference change value (RCV), index of individuality (IoI), and intraclass correlation coefficient (ICC) were determined. Analytic variability (CVa) from monthly testing was 1.2%, 1.1%, and 1.5% for sLDL, HDL3, and TRL, respectively. Monthly within-subject variability (CVw) was 17.1% for sLDL, 7.4% for HDL3 and 25.7% for TRL. Monthly between-subject variability (CVb) was 32.2%, 13.93%, and 33.4% for sLDL, HDL3, and TRL, respectively. Most of the monthly variation was attributed to between-subject variation for all three tests. Within-subject variation accounted for 37% of TRL variation and 22% for both sLDL and HLD3. Within-subject RCVs for monthly measurements were 16.9mg/dL for sLDL, 5.3mg/dL for HDL3, and 15.1mg/dL for TRL. IoIs for monthly testing were 0.81 for TRL, 0.57 for sLDL, and 0.61 for HDL3. Our data demonstrate that sLDL, HDL3, and TRL show low analytical variability, moderate within-subject variability, but high between-subject variability when measured by homogenous assays in a healthy population. The IoI value (>0.6) for TRL suggests use of a reference interval is appropriate for result interpretation. Conversely, clinical cut-points may be more useful than reference intervals for sLDL and HDL3 which had IoIs ~0.6. These findings may be useful for clinical interpretation, particularly when comparing successive measurements of these analytes.
S76 Endoscopic Ultrasound-Guided Fine Needle Aspiration for Suspected Pancreatic Malignancies in Chronic Pancreatitis: A Systematic Review and Meta-Analysis
Abdallah, Mohamed , Taha, Wesam, Abdalla, Abubaker , Musa, Abdullahi, Taha, Hassan, Hamad, Mohammed A. , Ahmed, Khalid , Hamad, Mohammed

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S33-S33

10.14309/01.ajg.0000772284.58929.ad Get It

Rheumatic Diseases: Diagnosis and Treatment . Eugene F. Traut. St. Louis: Mosby, 1952. 942 pp. Illus. $20.00
Polley, Howard F.

Mayo Clinic

Science | October 22, 2021 | Volume: 117 | Issue: 3043 | Pages: 463-463

10.1126/science.117.3043.463.b Get It

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
Benza, Raymond L. , Channick, Richard N. , Chin, Kelly , McLaughlin, Vallerie V. , Zamanian, Roham T. , Cravets, Matt , Bruey, Jean‐Marie, Roscigno, R.F., Mottola, David, Elman, Erin, Zisman, Lawrence S. , Ghofrani, Hossein‐Ardeschir, Chin, Kelly M , Benza, Raymond L. , Frantz, Robert P. , Channick, Richard N. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier , Hemnes, Anna R. , Ghofrani, Hossein‐Ardeschir

Mayo Clinic

Pulmonary Circulation | October 22, 2021 | Volume: 11 | Issue: 4 | Pages: 1-7

10.1177/20458940211057071 | PMID 34790348 Get It

Aberrant kinase signaling that involves platelet‐derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c‐KIT) pathways may be responsible for vascular remodeling in pulmonary arterial hypertension. Targeting these specific pathways may potentially reverse the pathological inflammation, cellular proliferation, and fibrosis associated with pulmonary arterial hypertension progression. Seralutinib (formerly known as GB002) is a novel, potent, clinical stage inhibitor of PDGFRα/β, CSF1R, and c‐KIT delivered via inhalation that is being developed for patients with pulmonary arterial hypertension. Here, we report on an ongoing Phase 2 randomized, double‐blind, placebo‐controlled trial (NCT04456998) evaluating the efficacy and safety of seralutinib in subjects with World Health Organization Group 1 Pulmonary Hypertension who are classified as Functional Class II or III. A total of 80 subjects will be enrolled and randomized to receive either study drug or placebo for 24 weeks followed by an optional 72‐week open‐label extension study. The primary endpoint is the change from baseline to Week 24 in pulmonary vascular resistance by right heart catheterization. The secondary endpoint is the change in distance from baseline to Week 24 achieved in the 6‐min walk test. A computerized tomography sub‐study will examine the effect of seralutinib on pulmonary vascular remodelling. A separate heart rate monitoring sub‐study will examine the effect of seralutinib on cardiac effort during the 6‐min walk test.
Repair of Large Nasal Septal Perforations Using the Upper Lateral Cartilage Mucosal Flap
Bansberg, Stephen F. , Taylor, Cullen M. , Howard, Brittany E. , Courson, Andy M., Miglani, Amar , Taylor, Cullen , Bansberg, Stephen F, Taylor, Cullen M, Howard, Brittany E, Courson, Andy M, Miglani, Amar

Mayo Clinic

The Laryngoscope | October 20, 2021 | Volume: 132 | Issue: 5 | Pages: 973-979

10.1002/lary.29901 | PMID 34661907 Get It

Objectives/HypothesisTo describe the surgical technique and closure outcomes of larger septal perforation repair incorporating mucosa from the undersurface of the upper lateral cartilage into a superiorly positioned advancement flap.Study DesignRetrospective case series.MethodsA chart review was performed for patients who underwent perforation repair utilizing bilateral nasal mucosal flaps which incorporated mucosa from the undersurface of the upper lateral cartilage into the superior flap between January 2009 and December 2020.ResultsSixty‐six patients met study criteria. Prior septal surgery was the most common (28.8%) etiology. Mean perforation length and height were 18.9 and 14.4 mm, respectively. Complete perforation closure was noted in 91.2% of patients followed for a minimum of 6 months (mean follow‐up time 32.1 months). Twelve patients underwent secondary surgery for persistent nasal obstruction. Postoperative loss of dorsal height was noted in seven patients. The NOSE‐perf scores were available for the last 15 repairs and demonstrated significant symptom improvement from a mean score of 26.4 (95% confidence interval [CI], 5.2) to 14.5 (95% CI, 5.2) (P < .0001).ConclusionThe ventral surface of the upper lateral cartilage can provide additional mucosa for incorporation into a superior advancement flap to achieve successful closure for larger septal perforations. Optimization of surgical outcomes for this challenging condition may require secondary functional or aesthetic procedures.Level of Evidence4 Laryngoscope, 132:973–979, 2022
Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases
Benatar, Michael , Wuu, Joanne , McHutchison, Caroline , Boeve, Bradley F. , Petersen, Ronald C. , Ross, Christopher A. , Rosen, Howard J. , Arias, Jalayne J. , Fradette, Stephanie , Stanislaw, Christine , Abrahams, Sharon, Cosentino, Stephanie , Grignon, Anne‐Laure , Rohrer, Jonathan D. , Al-Chalabi, Ammar, Workshop, First International Pre-Symptomatic ALS, Al-Chalabi, Ammar, Andersen, Peter M, Dave, Kuldip D. , Ferguson, Toby A. , Floeter, Mary-Kay, Grossman, Murray, Gubitz, Amelie K., Kaufman, Petra, Ber, Isabelle Le , Lee, Suzee, Malaspina, Andrea , Nicholson, Katie, Robinson, Richard , Stanislaw, Christine, Tatton, Nadine , Thakur, Neil , Weishaupt, Jochen H. , McDermott, Michael P. , Boeve, Brad , Ross, Christopher A , Stanislaw, Christine , Andersen, Peter Munch , Granit, Volkan , Turner, Martin R , Rohrer, Jonathan D , Postuma, Ronald B. , McDermott, Michael , Shefner, Jeremy M. , Finkel, Richard S. , McMillan, Corey T. , Grossman, Murray , Al-Chalabi, Ammar, Turner, Martin R. , Workshop, First International Pre-Symptomatic ALS, Al-Chalabi, Ammar, Andersen, Peter M, Floeter, Mary Kay, Gendron, Tania F. , Nicholson, Katie, Stanislaw, Christine

Mayo Clinic

Brain | October 19, 2021 | Volume: 145 | Issue: 1 | Pages: 27-44

10.1093/brain/awab404 | PMID 34677606 Get It

Abstract Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis. While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinal muscular atrophy and frontotemporal dementia are also each preceded by a pre-symptomatic or prodromal period of varying duration, during which the underlying disease process unfolds, with associated compensatory changes and loss of inherent system redundancy. Key insights from these diseases highlight opportunities for discovery in amyotrophic lateral sclerosis. The development of biomarkers reflecting amyloid and tau has led to a shift in defining Alzheimer’s disease based on inferred underlying histopathology. Parkinson’s disease is unique among neurodegenerative diseases in the number and diversity of non-genetic biomarkers of pre-symptomatic disease, most notably REM sleep behaviour disorder. Huntington’s disease benefits from an ability to predict the likely timing of clinically manifest disease based on age and CAG-repeat length alongside reliable neuroimaging markers of atrophy. Spinal muscular atrophy clinical trials have highlighted the transformational value of early therapeutic intervention, and studies in frontotemporal dementia illustrate the differential role of biomarkers based on genotype. Similar advances in amyotrophic lateral sclerosis would transform our understanding of key events in pathogenesis, thereby dramatically accelerating progress towards disease prevention. Deciphering the biology of pre-symptomatic amyotrophic lateral sclerosis relies on a clear conceptual framework for defining the earliest stages of disease. Clinically manifest amyotrophic lateral sclerosis may emerge abruptly, especially among those who harbour genetic mutations associated with rapidly progressive amyotrophic lateral sclerosis. However, the disease may also evolve more gradually, revealing a prodromal period of mild motor impairment preceding phenoconversion to clinically manifest disease. Similarly, cognitive and behavioural impairment, when present, may emerge gradually, evolving through a prodromal period of mild cognitive impairment or mild behavioural impairment before progression to amyotrophic lateral sclerosis. Biomarkers are critically important to studying pre-symptomatic amyotrophic lateral sclerosis and essential to efforts to intervene therapeutically before clinically manifest disease emerges. The use of non-genetic biomarkers, however, presents challenges related to counselling, informed consent, communication of results and limited protections afforded by existing legislation. Experiences from pre-symptomatic genetic testing and counselling, and the legal protections against discrimination based on genetic data, may serve as a guide. Building on what we have learned—more broadly from other pre-symptomatic neurodegenerative diseases and specifically from amyotrophic lateral sclerosis gene mutation carriers—we present a road map to early intervention, and perhaps even disease prevention, for all forms of amyotrophic lateral sclerosis.
Proposed research criteria for prodromal behavioural variant frontotemporal dementia
Barker, Megan S. , Gottesman, Reena , Manoochehri, Masood , Chapman, Silvia , Brushaber, Danielle , Devick, Katrina L. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Forsberg, Leah K. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Heuer, Hilary W. , Kornak, John , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F, Pascual, Belén , Staffaroni, Adam M. , Tartaglia, Maria Carmela , Boxer, Adam L. , Rosen, Howard J. , Rankin, Katherine P. , Cosentino, Stephanie , Rascovsky, Katya, Huey, Edward D. , Kaufer, Daniel , Onyike, Chiadi U. , Ritter, Aaron, Weıntraub, Sandra , Devick, Katrina L , Masdeu, Joseph C , Pascual, Belen , Boeve, Brad , Tartaglia, Maria Carmela , Domoto-Reilly, Kimiko , Appleby, Brian S. , Dickerson, Bradford Clark , Galasko, Douglas , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Knopman, David S. , Litvan, Irene , Mendez, Mario F, Boeve, Bradley F. , Foroud, Tatiana , Kremers, Walter K. , Léger, Gabriel C. , Roberson, Erik D.

Mayo Clinic

Brain | September 30, 2021 | Volume: 145 | Issue: 3 | Pages: 1079-1097

10.1093/brain/awab365 | PMID 35349636 Get It

Abstract At present, no research criteria exist for the diagnosis of prodromal behavioural variant frontotemporal dementia (bvFTD), though early detection is of high research importance. Thus, we sought to develop and validate a proposed set of research criteria for prodromal bvFTD, termed ‘mild behavioural and/or cognitive impairment in bvFTD’ (MBCI-FTD). Participants included 72 participants deemed to have prodromal bvFTD; this comprised 55 carriers of a pathogenic mutation known to cause frontotemporal lobar degeneration, and 17 individuals with autopsy-confirmed frontotemporal lobar degeneration. All had mild behavioural and/or cognitive changes, as judged by an evaluating clinician. Based on extensive clinical workup, the prodromal bvFTD group was divided into a Development Group (n = 22) and a Validation Group (n = 50). The Development Group was selected to be the subset of the prodromal bvFTD group for whom we had the strongest longitudinal evidence of conversion to bvFTD, and was used to develop the MBCI-FTD criteria. The Validation Group was the remainder of the prodromal bvFTD group and was used as a separate sample on which to validate the criteria. Familial non-carriers were included as healthy controls (n = 165). The frequencies of behavioural and neuropsychiatric features, neuropsychological deficits, and social cognitive dysfunction in the prodromal bvFTD Development Group and healthy controls were assessed. Based on sensitivity and specificity analyses, seven core features were identified: apathy without moderate-severe dysphoria, behavioural disinhibition, irritability/agitation, reduced empathy/sympathy, repetitive behaviours (simple and/or complex), joviality/gregariousness, and appetite changes/hyperorality. Supportive features include a neuropsychological profile of impaired executive function or naming with intact orientation and visuospatial skills, reduced insight for cognitive or behavioural changes, and poor social cognition. Three core features or two core features plus one supportive feature are required for the diagnosis of possible MBCI-FTD; probable MBCI-FTD requires imaging or biomarker evidence, or a pathogenic genetic mutation. The proposed MBCI-FTD criteria correctly classified 95% of the prodromal bvFTD Development Group, and 74% of the prodromal bvFTD Validation Group, with a false positive rate of &lt;10% in healthy controls. Finally, the MBCI-FTD criteria were tested on a cohort of individuals with prodromal Alzheimer’s disease, and the false positive rate of diagnosis was 11–16%. Future research will need to refine the sensitivity and specificity of these criteria, and incorporate emerging biomarker evidence.
Current directions in tau research: Highlights from Tau 2020
Sexton, Claire E. , Snyder, Heather M. , Boxer, Adam L. , Brannelly, Patrick , Brion, Jean‐Pierre , Buée, Luc , Cacace, Angela , Chételat, Gaël , Citron, Martin , DeVos, Sarah L. , Diaz, Kristophe , Feldman, Howard , Frost, Bess , Goate, Alison , Gold, Michael , Johnson, Keith A. , Kerwin, Diana , Mummery, Catherine J. , Mutamba, James, Quiroz, Yakeel T. , Rabinovici, Gil D. , Rommel, Amy, Shulman, Melanie , Toledo‐Sherman, Leticia , Weninger, Stacie, Wildsmith, Kristin R., Worley, Susan, Carrillo, María C. , Sexton, Claire , Patterson, Marc C. , Rabinovici, Gil D , Feldman, Howard H , Goate, Alison M , Beher, Dirk , Hyman, Bradley T. , Karch, Celeste M. , Koroshetz, Walter J. , Litvan, Irene , Morris, Huw R.

Mayo Clinic

Alzheimer's & Dementia | September 28, 2021 | Volume: 18 | Issue: 5 | Pages: 988-1007

10.1002/alz.12452 | PMID 34581500 Get It

AbstractStudies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau‐related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first‐ever Tau2020 Global Conference in Washington, DC, co‐organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research‐advancing tools and insights that are now rapidly accelerating the pace of tau research.
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Bagley, Stephen , Kothari, Shawn, Rahman, Rifaquat , Lee, Eudocia Q. , Dunn, Gavin P. , Galanis, Evanthia , Chang, Susan M. , Nabors, Burt , Ahluwalia, Manmeet S. , Stupp, Roger , Reardon, David A. , Khagi, Simon , Weller, Michael , Wen, Patrick Y. , Nabors, Louis Burt , Mehta, Minesh P , Sulman, Erik P , Weller, Michael , Khasraw, Mustafa , Galanis, Evanthia , Stupp, Roger , Ahluwalia, Manmeet S , Mehta, Minesh P. , Grossman, Stuart A. , Sulman, Erik P. , Sampson, John Howard , Cloughesy, Timothy F. , Wen, Patrick Yung , Khasraw, Mustafa

Mayo Clinic

Clinical Cancer Research | September 24, 2021 | Volume: 28 | Issue: 4 | Pages: 594-602

10.1158/1078-0432.ccr-21-2750 | PMID 34561269 Get It

Abstract Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as “recruiting” or “not yet recruiting” as of February 2021.